Geschlechtsspezifische Unterschiede in der Behandlungsrealität von Patientinnen und Patienten mit chronisch-entzündlichen Darmerkrankungen (CED)

Zusammenfassung

Die vorliegende Übersichtsarbeit gibt einen Überblick über die aktuelle Studienlage zu geschlechtsspezifischen Unterschieden in der Behandlungsrealität von Patienten mit chronisch-entzündlichen Darmerkrankungen (CED). Dabei wird auf den Krankheitsverlauf, die medikamentöse und chirurgische Therapie ebenso wie auf die psychosozialen Unterschiede zwischen Frauen und Männern mit CED eingegangen.

Abstract

This review focuses on the gender and sex dimorphic disease profile and treatment reality of patients suffering from inflammatory bowel diseases (IBD). It provides an overview of gender-specific differences in the disease course, medical and surgical therapy as well as psychosocial aspects of IBD.

Schlüsselwörter

CED - geschlechtsspezifische Therapie

Key words

IBD - gender issues

• Literatur

• 1 Wagtmans MJ, Verspaget HW, Lamers CB et al. Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol 2001; 96: 1541-1546
• 2 Calkins BM, Mendeloff AI. The epidemiology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter PG, eds Inflammatory bowel disease. 4th ed. Baltimore: Williams&Wilkins; 1995: 31-68
• 3 Kyle J. Crohn’s disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastroenterology 1992; 103: 392-399
• 4 Latour P, Louis E, Belaiche J. Incidence of inflammatory bowel disease in the area of Liège: a 3 years prospective study (1993-1996). Acta Gastroenterol Belg 1998; 61: 410-413
• 5 Shivananda S, Peña AS, Nap M et al. Epidemiology of Crohn’s disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology 1987; 93: 966-974
• 6 Whelan G. Epidemiology of inflammatory bowel disease. Med Clin North Am 1990; 74: 1-12
• 7 Brahme F, Lindström C, Wenckert A. Crohn’s disease in a defined population. An epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmö, Sweden. Gastroenterology 1975; 69: 342-351
• 8 Prideaux L, Kamm MA, De Cruz PP et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 27: 1266-80
• 9 Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001; 7: 260-270
• 10 Leong RW, Rupert WL, Lau JY et al. The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-651
• 11 Ng SC, Bernstein CN, Vatn MH et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut 2013; 62: 630-649
• 12 Virta L, Auvinen A, Helenius H et al. Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease – a nationwide, register-based finnish case-control study. Am J Epidemiol 2012; 175: 775-784
• 13 Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2687-2692
• 14 Andersson RE, Olaison G, Tysk C et al. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003; 124: 40-46
• 15 Lakatos PL, Vegh Z, Lovasz BD et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010-1017
• 16 Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J. Gastroenterol 2007; 13: 6134-6139
• 17 Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122
• 18 Peyrin-Biroulet L, Loftus EV, Tremaine WJ et al. Perianal Crohn’s disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis 2012; 18: 43-48
• 19 Greenstein AJ, Sachar DB, Panday AK et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71: 261-270
• 20 Wu X, Mukewar S, Kiran RP et al. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 2013; 7: e171-e177
• 21 Ampuero J, Rojas-Feria M, Castro-Fernández M et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol 2014; 29: 291-295
• 22 Romberg-Camps MJL, Dagnelie PC, Kester AD et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383
• 23 Mazor Y, Maza I, Kaufman E et al. Prediction of disease complication occurrence in Crohn’s disease using phenotype and genotype parameters at diagnosis. J Crohns Colitis 2011; 5: 592-597
• 24 Blumenstein I, Herrmann E, Filmann N et al. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 2011; 5: 203-210
• 25 Bokemeyer B, Hardt J, Hüppe D et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 2013; 7: 355-368
• 26 Høivik ML, Reinisch W, Cvancarova M et al. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther 2014; 39: 69-76
• 27 Walldorf J, Krummerl A, Engler K et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients?. J Crohns Colitis 2013; 7: 901-907
• 28 Wada Y, Hisamatsu T, Naganuma M et al. Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. Clin Nutr 2015; S0261-S5614 (15)00008-4
• 29 Robinson RJ, Al-Azzawi F, Iqbal SK et al. Osteoporosis and determinants of bone density patients with Crohn’s disease. Dig Dis Sci 1998; 43: 2500-2506
• 30 Bartram SA, Peaston RT, Rawlings DA et al. Multifactoral analysis of risk factors for reduced bone mineral density in patients with Crohn’s disease. World J Gastroenterol 2006; 12: 5680-5685
• 31 Ullman TA. Inflammatory bowel disease-associated cancers: does gender change incidence?. Gastroenterology 2010; 138: 1658-1660
• 32 Söderlund S, Granath F, Broström O et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138: 1697-1703
• 33 Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645
• 34 Bewtra M, Kaiser LM, TenHave T et al. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013; 19: 599-613
• 35 Lawrance IC, Willert RP, Murray K. A Validated Bowel-Preparation Tolerability Questionnaire and Assessment of Three Commonly Used Bowel-Cleansing Agents. Dig Dis Sci 2013; 58: 926-935
• 36 Bessissow T, van Keerberghen C, van Oudenhove L et al. Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. Journal of Crohn’s and Colitis 2013; 7: e580-e587
• 37 Thukkani N, Williams LJ, Sonnenberg A. Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis 2011; 17: 1333-1337
• 38 Koido S, Ohkusa T, Nakae K et al. Factors associated with incomplete colonoscopy at a Japanese academic hospital. World J. Gastroenterol 2014; 20: 6961-6967
• 39 Rimola J, Rodriguez S, Garcia-Bosch O et al. MR colonography in the evaluation of inflammatory bowel disease. Radiographics 2009; 29: 701-719
• 40 Shaw LJ, Shaw RE, Merz CN et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008; 117: 1787-1801
• 41 Caso V, Paciaroni M, Agnelli G et al. Gender differences in patients with acute ischemic stroke. Womens Health (Lond Engl) 2010; 6: 51-57
• 42 Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res. Ther 2009; 11: 252
• 43 Szalat A, Auryan S, Raz I et al. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab 2008; 10: 1135-1156
• 44 Harichand-Herdt S, Ramalingam SS. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin. Oncol 2009; 36: 572-580
• 45 Lesuis N, Befrits R, Nyberg F et al. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med 2012; 10: 82
• 46 Peyrin-Biroulet L, Harmsen WS, Tremaine WJ et al. Surgery in a Population-Based Cohort of Crohn’s Disease From Olmsted County, Minnesota. Am J Gastroenterol 2012; 107: 1693-1701
• 47 Hofer B, Böttger T, Hernandez-Richter T et al. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology 2001; 48: 152-155
• 48 Targownik LE, Singh H, Nugent Z et al. The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort. Am J Gastroenterol 2012; 107: 1228-1235
• 49 Samuel S, Ingle SB, Dhillon S et al. Cumulative Incidence and Risk Factors for Hospitalization and Surgery in a Population-based Cohort of Ulcerative Colitis. Inflamm Bowel Dis 2013; 19: 1858-1866
• 50 Rottoli M, Remzi FH, Shen B et al. Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Disease 2012; 14: 336-341
• 51 Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of Response and Need for Adalimumab Dose Intensification in Crohn’s Disease: A Systematic Review. Am J Gastroenterol 2011; 106: 674-684
• 52 Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn’s disease: A large single centre experience. Journal of Crohn’s and Colitis 2012; 6: 143-153
• 53 Long MD, Drossman DA. Editorial: Inflammatory Bowel Disease, Irritable Bowel Syndrome, or What? A Challenge to the Functional–Organic Dichotomy. Am J Gastroenterol 2010; 105: 1796-1798
• 54 Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1435-1446
• 55 Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-2137
• 56 Zelinkova Z, Bultman E, Vogelaar L et al. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. World J. Gastroenterol 2012; 18: 6967-6973
• 57 Yen L, Wu J, Hodgkins PL et al. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm 2012; 18: 701-712
• 58 Goodhand JR, Kamperidis N, Sirwan B et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38: 1097-1108
• 59 Zelante A, de Giorgi A, Borgoni R et al. Adherence to medical treatment in inflammatory bowel disease patients. Minerva Gastroenterol Dietol 2014; 60: 269-274
• 60 Trindade AJ, Ehrlich A, Kornbluth A et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011; 17: 599-604
• 61 Lopez A, Billioud V, Peyrin-Biroulet C et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2013; 19: 1528-1533
• 62 Long MD, Kappelman MD, Martin CF et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): Methodology and initial results. Inflamm Bowel Dis 2012; 18: 2099-2106
• 63 Mantzaris GJ, Roussos A, Kalantzis C et al. How adherent to treatment with azathioprine are patients with Crohn’s disease in long-term remission?. Inflamm Bowel Dis 2007; 13: 446-450
• 64 Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157-1166
• 65 López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 45-49
• 66 Sewitch MJ, Abrahamowicz M, Bitton A et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 1470-1479
• 67 Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006; 12: 697-707
• 68 Nahon S, Lahmek P, Durance C et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2086-2091
• 69 Häuser W, Janke K, Klump B et al. Anxiety and depression in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 621-632
• 70 Panara AJ, Yarur AJ, Rieders B et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther 2014; 39: 802-810
• 71 Walker JR, Ediger JP, Graff LA et al. The Manitoba IBD Cohort Study: A Population-Based Study of the Prevalence of Lifetime and 12-Month Anxiety and Mood Disorders. Am J Gastroenterol 2008; 103: 1989-1997
• 72 Maunder RG, de Rooy EC, Toner BB et al. Health-related concerns of people who receive psychological support for inflammatory bowel disease. Can J Gastroenterol 1997; 11: 681-685
• 73 Graff LA, Walker JR, Lix L et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol 2006; 4: 1491-1501
• 74 Nurmi E, Haapamäki J, Paavilainen E et al. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol 2013; 48: 51-57
• 75 Hauser G, Tkalcić M, Stimac D et al. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. Coll Antropol 2011; 35: 203-207
• 76 McDermott E, Mullen G, Moloney J et al. Body Image Dissatisfaction. Inflamm Bowel Dis 2015; 21: 353-360